Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barry, A. L.
Right arrow Articles by Tenover, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barry, A. L.
Right arrow Articles by Tenover, F. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 37, 365-369
© 1996 The British Society for Antimicrobial Chemotherapy

brief-report

In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits

A. L. Barrya, P. C. Fuchsa,b, S. D. Allenc, S. D. Browna, J. H. Jorgensend and F. C. Tenovere

aThe Clinical Microbiology Institute P.O. Box 947, Tualatin, Oregon 97062, USA bSt. Vincent Medical Center Portland, Oregon 97225 cIndiana University Medical Center, Indianapolis Indiana 46202 dUniversity of Texas Health Sciences Center San Antonio, Texas 78284 eCenters for Disease Control and Prevention Atlanta, Georgia 30333, USA

Received 5 July 1995; accepted 9 September 1995

The l-isomer of ofloxacin (levofloxacin) was twice as active as ofloxacin and the d-isomer was inactive against 654 Streptococcus pneumoniae isolates. For disc susceptibility tests of pneumococci, 5 µg levofloxacin discs can be used with interpretive criteria of≤12 mm for resistant (MIC≥8.0 mg/L) and≥16 mm for susceptible (MIC≤2.0 mg/L). For quality control of levofloxacin tests, S. pneumoniae ATCC 49619 should give zones 20–25 mm in diameter and MICs 0.5–2.0 mg/L.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
D. K. Chen, A. McGeer, J. C. de Azavedo, D. E. Low, and The Canadian Bacterial Surveillance Network
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
N. Engl. J. Med., July 22, 1999; 341(4): 233 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. H. Jorgensen, L. M. Weigel, M. J. Ferraro, J. M. Swenson, and F. C. Tenover
Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parE Loci
Antimicrob. Agents Chemother., February 1, 1999; 43(2): 329 - 334.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
P. D. Lister and C. C. Sanders
Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
J. Antimicrob. Chemother., January 1, 1999; 43(1): 79 - 86.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. K. Spangler, G. Lin, M. R. Jacobs, and P. C. Appelbaum
Postantibiotic Effect and Postantibiotic Sub-MIC Effect of Levofloxacin Compared to Those of Ofloxacin, Ciprofloxacin, Erythromycin, Azithromycin, and Clarithromycin against 20 Pneumococci
Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1253 - 1255.
[Abstract] [Full Text]

Home page
 J. Clin. Microbiol.Home page
J. H. Jorgensen, M. L. McElmeel, and S. A. Crawford
Evaluation of the Dade MicroScan MICroSTREP Antimicrobial Susceptibility Testing Panel with Selected Streptococcus pneumoniae Challenge Strains and Recent Clinical Isolates
J. Clin. Microbiol., March 1, 1998; 36(3): 788 - 791.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.